Biocon’s subsidiary -- Biocon Biologics (BBL) has received marketing authorisation from European Commission (EC) in the European Union (EU) for YESINTEK, a biosimilar of Ustekinumab.
YESINTEK is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn’s disease. Clinical data from the trial program showed that Ustekinumab biosimilar has comparable safety and efficacy to the originator product.
The marketing authorisation approval follows a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued on December 14, 2024.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
